Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonidine vs Articaine Buccal Infiltration for IANB Success
NCT04186299Phase 4Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of clonidine in irreversible pulpitis (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Evaluation of success of IANB at 4 hours. Planned start Aug 2021; status: withdrawn.
02
Drugs
clonidine
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on NCT04186299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186299.